34319
document
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes . BACKGROUND AND OBJECTIVES Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy . For examination of whether this is based on the same mechanisms as angiotensin II receptor blockers or thiazolidinedione , effects of sarpogrelate on atherosclerotic inflammatory molecules and their relations to albuminuria in patients who had diabetes and had already been treated with angiotensin II receptor blockers and with or without thiazolidinedione were examined . DESIGN , SETTING , PARTICIPANTS , & MEASUREMENTS Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker ( n = 40 ) were randomly assigned to sarpogrelate ( 300 mg/d ; n = 20 ) or aspirin group ( 100 mg/d ; n = 20 ) . Plasma monocyte chemoattractant protein-1 and urinary albumin-to-creatinine ratio and monocyte chemoattractant protein-1 were measured at baseline and 16 wk after administration . RESULTS Only the sarpogrelate group showed increases in plasma adiponectin and decreases in both plasma and urinary monocyte chemoattractant protein-1 and albumin-to-creatinine ratio levels . Moreover , percentage change of monocyte chemoattractant protein-1 level correlated positively to that of albumin-to-creatinine ratio . Even when the sarpogrelate group was further divided into two groups with ( n = 9 ) or without thiazolidinedione ( n = 11 ) , changes in monocyte chemoattractant protein-1 or albumin-to-creatinine ratio did not differ . CONCLUSIONS Sarpogrelate can reduce albuminuria and plasma and urinary monocyte chemoattractant protein-1 levels while increasing plasma adiponectin in diabetic nephropathy . These effects seem to be mediated via mechanisms that are different from those of angiotensin II receptor blocker or thiazolidinedione .
34320
Intervention_Pharmacological
sarpogrelate
34321
Intervention_Pharmacological
Sarpogrelate
34322
Intervention_Pharmacological
thiazolidinedione
34323
Intervention_Pharmacological
sarpogrelate
34324
Intervention_Pharmacological
angiotensin II receptor blockers
34325
Intervention_Pharmacological
thiazolidinedione
34326
Intervention_Pharmacological
angiotensin II receptor blocker
34327
Intervention_Pharmacological
sarpogrelate
34328
Intervention_Pharmacological
aspirin group
34329
Intervention_Pharmacological
sarpogrelate
34330
Intervention_Pharmacological
sarpogrelate
34331
Intervention_Pharmacological
thiazolidinedione
34332
Intervention_Pharmacological
Sarpogrelate
34333
Intervention_Pharmacological
angiotensin II receptor blocker
34334
Intervention_Pharmacological
thiazolidinedione
34335
Outcome_Physical
Plasma monocyte chemoattractant protein-1 and urinary albumin-to-creatinine ratio and monocyte chemoattractant protein-1
34336
Outcome_Physical
plasma adiponectin
34337
Outcome_Physical
plasma and urinary monocyte chemoattractant protein-1 and albumin-to-creatinine ratio levels .
34338
Outcome_Physical
percentage change of monocyte chemoattractant protein-1 level
34339
Outcome_Physical
monocyte chemoattractant protein-1 or albumin-to-creatinine ratio
34340
Participant_Condition
type 2 diabetes
34341
Participant_Condition
diabetes
34342
Participant_Sample-size
Forty
34343
Participant_Condition
diabetes
34344
Participant_Condition
nephropathy and arteriosclerosis obliterans